Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artios Pharma Ltd.

www.artiospharma.com

Latest From Artios Pharma Ltd.

Incubator Addition: Arix CIO On Why Fund Added VelosBio To Portfolio

Incubator fund Arix Bioscience has expanded its start-up portfolio to 15 by co-leading a series A financing for - and taking an equity stake in – antibody-drug conjugate specialist VelosBio. CIO Joe Anderson explains why.

Business Strategies Commercial

Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic

Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.

Companies Financing

Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter

Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.

Financing Regenerative Medicine

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
Financing Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Artios Pharma Ltd.
  • Senior Management
  • Niall Martin, PhD, CEO
    Andrew Muncey, CFO
    Graeme Smith, PhD, CSO
    Nick Staples, PhD, CBO
    Peter Harris, CMO
  • Contact Info
  • Artios Pharma Ltd.
    Phone: 1223 804180
    c/o The Babraham Institute
    Meditrina B260
    Babraham, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register